Introduction
Patients with Crohn’s disease (CD) who have undergone ileostomy represent a population previously and routinely excluded from randomised controlled clinical trials. This constrains understanding of their disease progression, treatment responsiveness, and appropriate endpoints. AZD7798 is a first-in-class therapeutic antibody that depletes CCR9+ lymphocytes, with potential for targeted treatment of ileal inflammation in CD.
Aims & Methods
CALLISTO (NCT06681324) is a Phase II study designed to: (i) characterise disease activity and clinical assessment feasibility in patients with an ileostomy and recurrent small bowel CD; (ii) generate first-in-population evidence on safety and tolerability of AZD7798; and (iii) explore whether AZD7798 can induce small bowel mucosal healing proximal to the stoma. In this interim report, we present key elements of recruitment feasibility and baseline characteristics of this entirely novel population for interventional clinical trials. Participants with active CD and an established ileostomy were enrolled across 21 sites in seven countries. Key eligibility criteria included centrally read endoscopically confirmed inflammation in the ileal segment 5-25 cm proximal to the stoma. Baseline assessments included ileal endoscopy, stoma effluent calprotectin, medical history, and patient-reported outcomes (PRO) using a
developed stoma-specific measure (patient-reported questions) capturing ileostomy-specific symptoms. Feasibility metrics included recruitment yield, technical feasibility of serial ileoscopy, and concordance between symptoms, biomarkers and endoscopic disease activity.
Results
Baseline data from 18 randomised participants are presented (Table). In total, 40 patients were screened, of whom 55% were excluded, principally for not meeting the centrally read endoscopic inclusion criterion of SES-CD score ≥ 4.
Baseline data
| Age [yrs], Gender male/female [n]
| Disease duration [yrs]
| Time since ileostomy [yrs]
| Prior advance therapies, Prior different MoA [n] | SES-CD
| Ostomy emptying per day [n]
| Stoma effluent calprotectin [µg/g]
| CRP [mg/L] |
Mean (min-max)
| 37 (20-71), 11 M/7 F
| 17 (2-32)
| 7 (0.6-26)
| 3.8 (1-8), 2.8 (1-5)
| 4.8 (4-7)
| 6 (3-10)
| 398 (<30-2,500)
| 13 (0.2-81.3)
|
Serial endoscopic access to the ileal segment proximal to the stoma was achievable, with no major technical limitations reported. Collection and measurement of calprotectin from stoma effluent was feasible. Pairwise correlations between baseline variables and multiple regression analyses showed no apparent relationship with ileal segment SES-CD, highlighting the challenge of pre-identifying endoscopically accessible active mucosal disease from non-imaging measures alone.
Conclusion
This baseline analysis represents the first systematic characterization of CD patients with an ileostomy within a prospective interventional trial. The data demonstrate that recruitment and assessment strategies need to account for substantial discordance between clinical symptoms and biomarkers, and endoscopically visible mucosal inflammation. Importantly, serial ileoscopies and stoma-based biomarker sampling were feasible, supporting the conduct of mechanistically focused trials in this setting. Collectively, these findings help establish a framework for disease assessment and trial design for an under-represented patient population and underscore the need for tailored endpoints and bespoke inclusion strategies.
Disclosure
BV report research support from AbbVie, Biora Therapeutics, Celltrion, Landos, Pfizer, Sanofi, Sossei Heptares/Nxera and Takeda. Speaker’s fees from Abbvie, Agomab, Alfasigma, Biogen, Bristol Myers Squibb, Celltrion, Eli Lily, Falk, Ferring, Galapagos, Materia Prima, Johnson and Johnson, Pfizer, Sandoz, Takeda, Tillots Pharma, Truvion and Viatris. Consultancy fees from AbbVie, Agomab, Alfasigma, Alimentiv, Anaptys Bio, Applied Strategic, AstraZeneca, Atheneum, BenevolentAI, Biora Therapeutics, Boxer Capital, Bristol Myers Squibb, Domain Therapeutics, Eli Lily, Galapagos, Guidepont, Landos, Merck, Mirador Therapeutics, Mylan, Nxera, Inotrem, Ipsos, Johnson and Johnson, Onco3R, Pallisade Bio, Pfizer, Sandoz, Sanofi, Santa Ana Bio, Sapphire Therapeutics, Sosei Heptares, Takeda, Tillots Pharma and Viatris. Stock options Vagustim and Thethis Pharma.
PM report grants from Janssen, Takeda, Ferring. Personal Fees: Ferring, Takeda, Abbvie, Tillotts Pharma, Janssen, Galapagos, AstraZeneca, Baxter, MSD. Other: Pfizer, Takeda.
JOL report consultancy fees from AbbVie, AstraZeneca, BMS, Celgene, Celltrion, Engytix, Ferring, Galapagos, Gilead, GSK, Janssen, Lilly, MSD, Orchard, Pfizer, Shattuck Labs and Takeda; has received speaker fees and travel support from AbbVie, Ferring, Galapagos, Gilead, High5MD, Janssen, Lilly, Materia Prima, MSD, Pfizer, Tillotts, and Takeda; and has received investigator-led research grants from AbbVie, Gilead, Pfizer, and Takeda.
ML report consultancy/lecture fees from AbbVie, Eli Lilly, Alfasigma, Janssen-Cilag, Johnson & Johnson, Pfizer, Takeda and Tillotts. These fees are invoiced by the speaker fee desk of the university. He has received grants from Alfasigma, NFU, ZonMW and TKI.
JRN reports fees for oral presentation: Dr Falk. Support for attending meetings / Congresses: Lilly, AbbVie, Dr Falk and Celltrion.
JK report grant from Nestle.
PL, SS, EF, NE, ME and DM are employees of AstraZeneca.